UP!

BRKS $44.28   View long term graphs

Brooks Automation
Type
Public
Traded as NASDAQ: BRKS
S&P 600 Component
Industry Semiconductor Equipment & Materials
Founded 1978
Headquarters Chelmsford, Massachusetts, United States
Key people

Dr. Stephen S. Schwartz (CEO), Mark D. Morelli ( President and Chief Operating Officer)

Lindon G. Robertson ( Chief Financial Officer) (Dec 31, 2013)
Revenue $ 477.51M(Dec 31, 2013)
Number of employees
1471 (Dec 31, 2013)
Website www.brooks.com

Dr. Stephen S. Schwartz (CEO), Mark D. Morelli ( President and Chief Operating Officer)

Brooks Automation was set up in 1978 and is now based in Chelmsford, Massachusetts. Brooks Automation is a provider of automation, vacuum and instrumentation equipment for multiple markets, including semiconductor manufacturing, technology device manufacturing and life sciences. Brooks Automation operates in four segments: Brooks Product Solutions, Brooks Global Services and Brooks Life Science Systems.

Brooks Automation was set up in 1978 and incorporated in 1994.

In 2002, Brooks Automation, Inc. completed the acquisition of Intelligent Automation Systems, Inc. of Cambridge, Massachusetts, a custom automation company with technology and products for the semiconductor, photonics and life sciences industries.

Brooks Automation acquired the Celigo automated Cell Cytometer product line from Cyntellect, Inc in 2011. The next year the company acquired intangible assets from Intevac, Inc. and acquired Crossing Automation Inc.

In October 2012, Brooks Automation entered into an agreement to acquire Crossing Automation Inc.

In April 2014, Brooks Automation entered into an agreement to sell its Granville-Phillips division to MKS Instruments.

Brooks closed the sale of Granville-Phillips to MKS Instruments on May 30, 2014.

Brooks Automation provides mainly four kinds: semiconductor automation and life science systems equipment, gas analysis and vacuum measurement, cryopumps, cryochillers and compressors, asset tracking equipment. The company features in developing and building the handling system and related technology. Automation products are used to support both atmospheric and vacuum based processes while the company's focus remains on improving performance and productivity. The company provides vacuum pumps and instrumentation to maintain pressure consistency of the known process gas. The Brooks Life Science Systems provides automated sample management systems and equipment, such as automated blood fractionation equipment, cellular imaging and consumables parts.

Brooks Automation won the R&D 100 award (100 most technologically significant new products introduced) by R&D Magazine for its Model 830 Vacuum Quality Monitor (VQMTM). VQMTM was used to determine gas composition with an electrostatic autoresonant ion trap.

News

Brooks Automation, Inc. -1.3% (technology)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q1 2021 2021-02-04 Future report Set alerts
Q4 2020 2020-11-04 Future report Set alerts
Q3 2020 2020-07-30 0.32 0.19
Q2 2020 2020-04-30 0.25 0.12
Q1 2020 2020-02-06 0.23 0.18
Q4 2019 2019-11-06 0.24 0.07
Q3 2019 2019-08-01 0.20 0.01
Q2 2019 2019-04-29 0.17 -0.04
Q1 2019 2019-02-05 0.17 0.09
Q4 2018 2018-11-19 0.40 -0.02

Ratings

2016-06-07 Reiterated Rating B. Riley Buy $16.50
2016-06-02 Reiterated Rating B. Riley Buy $16.50
2016-05-04 Reiterated Rating B. Riley Buy $16.50
2016-04-29 Reiterated Rating Credit Suisse Sell $9.80
2016-04-29 Reiterated Rating B. Riley Buy $16.50
2016-04-29 Reiterated Rating Credit Suisse Group AG Sell $9.80
2016-03-16 Reiterated Rating Credit Suisse Underperform $10.00
2016-03-14 Reiterated Rating B. Riley Buy $16.50
2016-03-09 Reiterated Rating B. Riley Buy $16.50
2016-03-08 Lower Price Target Credit Suisse Underperform $10.00 to $9.10
2016-03-04 Reiterated Rating B. Riley Buy $16.50
2016-02-09 Reiterated Rating B. Riley Buy $16.50
2016-02-04 Lower Price Target Credit Suisse Underperform $10.00 to $9.10
2016-02-04 Boost Price Target B. Riley Buy $15.50 to $16.50
2015-11-11 Reiterated Rating B. Riley Buy $15.50
2015-11-06 Reiterated Rating Needham & Company LLC Buy $14.00 to $13.00
2015-11-06 Reiterated Rating B. Riley Buy $15.50
2015-10-09 Lower Price Target Needham & Company LLC Buy $15.00 to $14.00
2015-08-14 Reiterated Rating Citigroup Inc. Hold $12.50 to $12.00
2015-08-12 Reiterated Rating B. Riley Buy $15.50
2015-08-07 Reiterated Rating B. Riley Buy $15.50
2015-06-29 Initiated Coverage Deutsche Bank Hold
2015-06-29 Initiated Coverage Deutsche Bank AG Hold
2015-05-01 Reiterated Rating B. Riley Buy $15.50
2015-02-06 Reiterated Rating B. Riley Buy $14.50
2015-01-20 Reiterated Rating Credit Suisse Underperform $10.00
2014-12-17 Reiterated Rating B. Riley Buy $14.50
2014-11-13 Boost Price Target Stifel Nicolaus $15.00
2014-11-05 Downgrade Sidoti Buy to Neutral
2014-11-04 Reiterated Rating Citigroup Inc. Neutral $11.50 to $12.50
2014-10-07 Initiated Coverage Furey Research Partners Buy $17.00
2014-10-07 Initiated Coverage CRT Capital Buy $17.00
2014-06-27 Upgrade Stifel Nicolaus Hold to Buy $13.00
2014-05-27 Upgrade B. Riley Neutral to Buy $9.50 to $12.50
2014-05-09 Lower Price Target B. Riley $10.50 to $9.50
2014-04-22 Reiterated Rating Citigroup Inc. Neutral $11.50
2014-03-17 Reiterated Needham Buy $11 to $13
2014-03-17 Boost Price Target Needham & Company LLC Buy $11.00 to $13.00
2014-02-07 Lower Price Target Needham & Company LLC $12.00 to $11.00
2013-11-18 Reiterated Rating Citigroup Inc. Neutral $9.50 to $10.50
2013-11-15 Reiterated Northland Capital Outperform $11 to $12
2013-11-15 Boost Price Target Needham & Company LLC Buy $11.00 to $12.00
2013-11-15 Boost Price Target Northland Securities Outperform $11.00 to $12.00
2013-11-08 Reiterated Rating Northland Securities Positive
2013-07-15 Reiterated Needham Buy $11 to $12
2012-10-02 Downgrade Barclays Equal Weight to Underweight
2012-01-30 Upgrade Brigantine Hold to Buy $13.50
2011-06-29 Reiterated Needham Buy $15 to $13
2011-04-25 Downgrade Brigantine Buy to Hold
2011-02-07 Downgrade Stifel Nicolaus Buy to Hold
2010-10-11 Initiated Brigantine Buy $12
2010-09-07 Downgrade Barclays Capital Overweight to Equal Weight $13 to $6
2010-04-07 Initiated Brigantine Buy $12
2010-02-08 Reiterated Credit Suisse Neutral $6 to $6.50
2016-06-07 Reiterated Rating B. Riley Buy $16.50
2016-06-02 Reiterated Rating B. Riley Buy $16.50
2016-05-04 Reiterated Rating B. Riley Buy $16.50
2016-04-29 Reiterated Rating Credit Suisse Sell $9.80
2016-04-29 Reiterated Rating B. Riley Buy $16.50

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
SCHWARTZ STEPHEN S President, CEO 0.92%  (617264) BRKS /
HEADLEY MARTIN S EVP & Chief Financial Officer 0.76%  (506741) BRKS /
Morelli Mark D EVP - Chief Operating Officer 0.62%  (414944) BRKS / CMCO /
Steven A. Michaud SVP, Brooks Product Solutions 0.33%  (221215) BRKS /
Robertson Lindon G EVP & Chief Financial Officer 0.24%  (158853) BRKS / GTI /
Tenney Maurice H. President-Brooks Life Sciences 0.23%  (156798) BRKS / PKI /
Haris Clinton M. SVP, Brooks Life Sciences 0.23%  (151374) BRKS / ENTG /
Leitzke Thomas SVP, Global Operations 0.21%  (139819) BRKS /
Montone William T. SVP, Human Resources 0.19%  (125847) BRKS /
Mirchandani Kush SVP, Worldwide Sales 0.18%  (120792) BRKS /
Joseph Jason VP, General Counsel, Secretary 0.17%  (116250) BRKS /
WRIGHTON MARK S 0.15%  (102722) BRKS / CBT / GLW /
Gray David C Chief Strategy & New Business 0.14%  (91806) BRKS /
Palepu Krishna G. 0.14%  (91243) BRKS /
MARTIN JOSEPH R 0.13%  (85468) BRKS / CLCT /
WOOLLACOTT ALFRED III 0.13%  (85058) BRKS /
ALLEN A CLINTON 0.11%  (75563) BRKS / CLCT / LKQ / PMD /
Mathews Timothy S Principal Accounting Officer 0.08%  (55846) BRKS / EIGI /
Pietrantoni David Principal Accounting Officer 0.08%  (52714) BRKS /
Zane Ellen M 0.07%  (45750) BRKS / BSX / HAE / PRXL /
PARK CHONG SUP 0.05%  (36645) BRKS / CSC / ENPH / STX /
Jarzynka David Sr. VP, General Manager 0.04%  (25618) BRKS /
MCGILLICUDDY JOHN K 0.01%  (9500) BRKS / CBT / WTS /
Davis Robyn C 0.01%  (7134) BRKS /

Comments